Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

BACKGROUND: The sodium–glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes. The efficacy and safety of this drug have not been properly defined in patients wi...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Nephrol Dial Transplant
Main Authors: Dekkers, Claire C J, Wheeler, David C, Sjöström, C David, Stefansson, Bergur V, Cain, Valerie, Heerspink, Hiddo J L
Formáid: Artigo
Teanga:Inglês
Foilsithe: Oxford University Press 2018
Ábhair:
ORIGINAL ARTICLES
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6212718/
https://ncbi.nlm.nih.gov/pubmed/29370424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfx350
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla